根据病毒衣壳表面有无囊膜结构, 病毒可被分为无包膜病毒和有包膜病毒。包膜病毒的膜蛋白在病毒的吸附、侵入、脱壳、生物大分子合成、病毒粒子的装配与释放等生命周期中起重要作用。某些包膜病毒的膜蛋白对病毒侵入宿主细胞的膜融合是不可或缺的。结构分析显示, Ⅰ型和Ⅱ型病毒融合蛋白采用类似的膜融合方式。此外, 流行性感冒病毒的M2 蛋白、人类免疫缺陷病毒Ⅰ型( HIV-1) 的Vpu 蛋白、重症急性呼吸综合征冠状病毒( SARS-CoV) 3a蛋白等膜蛋白还具有离子通道的功能。针对这些病毒膜融合蛋白设计的抑制分子, 将为研发抗包膜病毒新型药物提供新思路和策略。本文以3 种病毒膜融合蛋白为例, 对其融合机制、跨膜蛋白离子通道功能及其在抗病毒药物设计中的应用作一简要综述

Viruses have been classified into enveloped and non-enveloped subtypes according to their surface structures. The membrane proteins of the enveloped viruses are involved in the attachment, penetration, ncoating,
replication, and release of the viruses. The special membrane proteins are essential for the membrane fusion bywhich the enveloped viruses penetrate into host cells. Furthermore, structural data showthat class I and class II viral fusion proteins utilize a similar principle in membrane fusion. In addition, there are some viral membrane proteins, such as M2 of the influenza virus, Vpu of the human immunodeficiency virus type 1 ( HIV-1) , 3a of the severe acute respiratory syndrome coronavirus ( SARS-CoV) , among others, that have ion channel functions. The processes involved in viral membrane fusion and ion channel function provide newinsights into therapeutic design and proteins as potential targets of antivirals. Here we give three typical viral membrane fusion proteins as examples to reviewthe mechanisms of viral membrane fusion and viral ion channel function and the strategies of antiviral drug design.